Strides Pharma Science Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 10,376.68 million compared to INR 8,648.46 million a year ago. Revenue was INR 10,464.22 million compared to INR 8,910.46 million a year ago. Net income was INR 496.67 million compared to net loss of INR 800.26 million a year ago. Basic loss per share from continuing operations was INR 0.49 compared to INR 8.86 a year ago. Diluted loss per share from continuing operations was INR 0.49 compared to INR 8.86 a year ago. Basic earnings per share was INR 5.43 compared to basic loss per share of INR 8.86 a year ago. Diluted earnings per share was INR 5.42 compared to diluted loss per share of INR 8.86 a year ago.
For the nine months, sales was INR 29,670.89 million compared to INR 27,020.17 million a year ago. Revenue was INR 30,203.36 million compared to INR 27,652.24 million a year ago. Net loss was INR 887.89 million compared to INR 1,930.93 million a year ago. Basic loss per share from continuing operations was INR 15.76 compared to INR 23.52 a year ago. Diluted loss per share from continuing operations was INR 15.76 compared to INR 23.52 a year ago. Basic loss per share was INR 9.79 compared to INR 21.45 a year ago. Diluted loss per share was INR 9.79 compared to INR 21.45 a year ago.